CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nanney, L. B.
Right arrow Articles by Carpenter, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nanney, L. B.
Right arrow Articles by Carpenter, G.

Cell Growth & Differentiation, Vol 3, Issue 4 233-239, Copyright © 1992 by American Association of Cancer Research


ARTICLES

Altered distribution of phospholipase C-gamma 1 in benign hyperproliferative epidermal diseases

LB Nanney, RE Gates, G Todderud, LE King Jr and G Carpenter
Department of Plastic Surgery and Cell Biology, Vanderbilt University, Nashville, Tennessee 37232.

Phospholipase C-gamma 1 (PLC-gamma 1) is a well characterized substrate for the epidermal growth factor receptor tyrosine kinase and has been implicated in the intracellular biochemical signaling cascade which occurs following stimulation of cells with epidermal growth factor. The in vivo localization of PLC-gamma 1 was examined by immunohistochemistry in sections of normal human skin and in skin sections from a diverse series of hyperproliferative epidermal conditions (psoriasis, seborrheic keratoses, acrochordons, and margins near second-degree burns). Immunoreactive PLC-gamma 1 was detected only in the basal compartment of normal skin but was readily detectable in both the basal and outer epidermal compartment in hyperproliferative skin conditions. In addition, immunoreactive PLC-gamma 1 colocalizes with immunoreactive epidermal growth factor receptor in both normal and hyperproliferative epidermis.


This article has been cited by other articles:


Home page
FASEB J.Home page
S. Y. SHIN, J. KO, J.-S. CHANG, D. S. MIN, C. CHOI, S. S. BAE, M. J. KIM, D. S. HYUN, J.-H. KIM, M. Y. HAN, et al.
Negative regulatory role of overexpression of PLC{gamma}1 in the expression of early growth response 1 gene in rat 3Y1 fibroblasts
FASEB J, October 1, 2002; 16(12): 1504 - 1514.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
Z. Xie and D. D. Bikle
Cloning of the Human Phospholipase C-{gamma}1 Promoter and Identification of a DR6-type Vitamin D-responsive Element
J. Biol. Chem., March 7, 1997; 272(10): 6573 - 6577.
[Abstract] [Full Text] [PDF]


Home page
J Biol ChemHome page
S.-J. Lee, S. D. Lee, J.-G. Park, C.-M. Kim, S. H. Ryu, and P.-G. Suh
Overexpression of Phospholipase C-{gamma}1 in Colorectal Carcinomas Is Associated with Overexpression of Factors That Bind Its Promoter
J. Biol. Chem., July 7, 1995; 270(27): 16378 - 16384.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
N C Luetteke, H K Phillips, T H Qiu, N G Copeland, H S Earp, N A Jenkins, and D C Lee
The mouse waved-2 phenotype results from a point mutation in the EGF receptor tyrosine kinase.
Genes & Dev., February 15, 1994; 8(4): 399 - 413.
[Abstract] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1992 by the American Association of Cancer Research.